# A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Source: https://onco.cc/trials/nct04802759/  
OnCo record `nct04802759` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer is a phase 1/2 interventional study registered as NCT04802759 by Hoffmann-La Roche, with 316 participants planned, started 2021-06-22 and due to reach its primary completion in 2029-05-30. Interventions recorded: Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04802759
- Phase: 1/2
- Setting: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)
- Sponsor: Hoffmann-La Roche
- Enrolled: 316

## Sources

- ClinicalTrials.gov NCT04802759: https://clinicaltrials.gov/study/NCT04802759

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Everolimus](https://onco.cc/drugs/everolimus/), [Giredestrant](https://onco.cc/drugs/giredestrant/), [Inavolisib](https://onco.cc/drugs/inavolisib/), [Ipatasertib](https://onco.cc/drugs/ipatasertib/), [Ribociclib](https://onco.cc/drugs/ribociclib/), [Samuraciclib](https://onco.cc/drugs/samuraciclib/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct04802759.json